US FDA’s Project Facilitate Making Some Improvements To Expanded Access
Analysis presented at ASCO concludes that pilot program helped physicians request access to investigational drugs for individual patients. Now agency officials are suggesting an expansion of the project.
You may also be interested in...
New call center is designed to help physicians navigate the expanded access pathway for oncology products, but FDA officials are unsure about how much interest it will generate.
Even as the US FDA can expect to be put through the ringer with the congressional and HHS Inspector General probes, the process could have some upsides for the agency, according to former officials who have been through such scrutiny.
Lilly appeared to benefit from agency’s increased familiarity in treating COVID-19 with these types of biologics. Changing nature of the pandemic and the loss of utility of older antibodies due to the Omicron variant may have also played a role in the data required for latest EUA.